Is There A Role for Radiotherapy In Experimental Therapeutic Drug Development?

results suggest that most pharmaceutical companies do not consider radiation-drug combinations as a pathway to registration or a means of expanding the indication of an agent. Future radiation therapy and drug or biologic therapy combination clinical trials might build upon more structured preclinical radiobiology with wider support from Industry to forecast clinical success [4].

References

 US Department of Health and Human Services, U.S. Food and Drug Administration (2007) Guidance for industry: dinical trial endpoints for the approval of cancer drugs and biologics.

- US Department of Health and Human Services, U.S. Food and Drug Administration (2012) Erbitux®(cetuximab).
- 3 US Department of Health and Human Services, U.S. Food and Drug Administration (2006) Temodar® (temozolonmide).

4